CVR number 36701544
Industry 75.0000 Veterinary activities

Ørslev Dyreklinik af 2015 ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  4.2% 9.6% 6.3% 4.7% 4.5%  
Credit score (0-100)  49 26 36 45 45  
Credit rating  BBB BB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Net sales  0 0 0 0 0  
Gross profit  1,501 1,700 1,870 1,851 2,037  
EBITDA  281 152 263 107 169  
EBIT  119 20.2 136 67.1 118  
Pre-tax profit (PTP)  104.0 15.6 134.3 24.4 53.7  
Net earnings  81.0 12.0 104.8 17.1 41.7  
Pre-tax profit without non-rec. items  104 15.6 134 24.4 53.7  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Tangible assets total  74.0 125 90.2 1,358 1,425  
Shareholders equity total  93.0 -10.1 94.7 112 153  
Interest-bearing liabilities  150 0.0 1.1 1,344 1,088  
Balance sheet total (assets)  735 624 510 1,912 1,720  
Net Debt  -65.0 -134 -169 1,000 1,017  
 
See the entire balance sheet

Volume 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,501 1,700 1,870 1,851 2,037  
Gross profit growth  13.9% 13.3% 10.0% -1.0% 10.1%  
Employees  0 0 0 0 5  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  735 624 510 1,912 1,720  
Balance sheet change%  3.6% -15.1% -18.3% 274.8% -10.0%  
Added value  281.0 151.9 263.2 194.6 169.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -270 -173 -255 1,220 16  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  3.0 4.0 5.0 5.0 5.0  

Profitability 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  7.9% 1.2% 7.3% 3.6% 5.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  16.8% 3.0% 23.7% 5.5% 6.5%  
ROI %  39.4% 16.2% 283.5% 8.7% 8.7%  
ROE %  153.8% 3.4% 29.2% 16.5% 31.4%  

Solidity 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Equity ratio %  12.8% -1.6% 18.6% 5.8% 8.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -23.1% -88.2% -64.1% 932.5% 600.8%  
Gearing %  161.3% 0.0% 1.1% 1,202.5% 709.1%  
Net interest  0 0 0 0 0  
Financing costs %  7.1% 7.0% 265.1% 6.4% 5.3%  

Liquidity 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Quick Ratio  0.5 0.4 0.6 0.4 0.2  
Current Ratio  0.7 0.6 1.0 0.6 0.4  
Cash and cash equivalent  215.0 134.0 169.7 344.0 70.8  

Capital use efficiency 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -159.0 -235.5 -3.2 -405.7 -448.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 34  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 34  
EBIT / employee  0 0 0 0 24  
Net earnings / employee  0 0 0 0 8